English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

As of February 2021, cumulative high-certainty data shows that Tocilizumab decreases the risk of mechanical ventilation in hospitalized patients with Covid-19 [1]. COVID-19 patients receiving tocilizumab may have a theoretical risk of acquiring a secondary infection due to immunosuppression [2]. Here we present a series of chest radiographs of a patient presented with severe Covid pneumonia who improved rapidly with tocilizumab but died of secondary infection later on.

Life-threatening secondary infection in a patient with Covid-19 pneumonia treated with tocilizumab: A picture series